Compare Johnson & Johnson (JNJ) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Target Corporation — how do they compare? Johnson & Johnson trades at $260.79 (market cap $618.09B), while Target Corporation trades at $153.81 (market cap $70.31B). The key difference: Johnson & Johnson is far larger — about 8.8× Target Corporation's market cap, and Target Corporation pays the higher dividend (3%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Target Corporation for 137 Days on average.
| JNJ | TGT | |
|---|---|---|
Market Cap | $618.09B | $70.31B |
Volume | 6,050,983 | 4,164,999 |
Sector | Health | Consumer Staples |
52-Week High | $278.43 | $169.90 |
52-Week Low | $186.00 | $83.68 |
Typical Hold Time | 129 Days | 137 Days |
Enterprise Value | $646.37B | $83.58B |
Dividend Yield | 2.09% | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Target Corporation (TGT) trades at $154.56, up 2.38% with strong recent earnings beats and positive analyst sentiment. The stock shows bearish technical signals but maintains solid fundamentals with a 4.08% net margin and 26.41% ROE. Recent price cuts on 2,000 items aim to capture holiday market share, while consistent dividend payments reinforce shareholder returns. Valuation metrics appear reasonable with P/E of 16.05 and P/S of 0.65.
Target presents a balanced opportunity with analyst consensus pointing to 8% upside to the $167.18 price target. The turnaround strategy shows early success, but competitive pressures and margin compression from price investments remain key risks. Institutional support remains strong with 60 analyst coverage favoring buy/hold positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
